FULGENT GENETICS, INC. Accounts Receivable, Allowance for Credit Loss, Writeoff
FULGENT GENETICS, INC. (FLGT) reported Accounts Receivable, Allowance for Credit Loss, Writeoff of $749.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Notes › and Others › Accounts, Notes, Loans and Financing Receivable, Gross, Allowance, and Net
us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs · last filed 2026-07-30
- FULGENT GENETICS, INC. accounts receivable, allowance for credit loss, writeoff for the quarter ending 2026-06-30 was -$824.00K, a 130.71% decline year-over-year.
- FULGENT GENETICS, INC. accounts receivable, allowance for credit loss, writeoff for the quarter ending 2026-03-31 was $1.57M, a 4.26% decline year-over-year.
- FULGENT GENETICS, INC. accounts receivable, allowance for credit loss, writeoff for the quarter ending 2025-12-31 was $2.13M, a 68.94% decline year-over-year.
- FULGENT GENETICS, INC. accounts receivable, allowance for credit loss, writeoff for the quarter ending 2025-09-30 was $469.00K, a 67.77% decline year-over-year.
- FULGENT GENETICS, INC. accounts receivable, allowance for credit loss, writeoff for fiscal 2025 was $6.92M, a 37.96% decline from fiscal 2024.
- FULGENT GENETICS, INC. accounts receivable, allowance for credit loss, writeoff for fiscal 2024 was $11.15M, a 26.12% decline from fiscal 2023.
- FULGENT GENETICS, INC. accounts receivable, allowance for credit loss, writeoff for fiscal 2023 was $15.10M, a 478.95% increase from fiscal 2022.
- FULGENT GENETICS, INC. accounts receivable, allowance for credit loss, writeoff for fiscal 2022 was $2.61M, a 422.65% increase from fiscal 2021.
| Period end | Accounts Receivable, Allowance for Credit Loss, Writeoff 3 month | Accounts Receivable, Allowance for Credit Loss, Writeoff 6 month | Accounts Receivable, Allowance for Credit Loss, Writeoff 9 month | Accounts Receivable, Allowance for Credit Loss, Writeoff 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$824.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $749.00K 10-Q · filed 2026-07-30 | $2.88M derived: sum of 3 quarters · filed 2026-07-30 | $3.34M derived: sum of 4 quarters · filed 2026-07-30 |
| 2026-03-31 | $1.57M 10-Q · filed 2026-05-01 | $3.70M derived: sum of 2 quarters · filed 2026-05-01 | $4.17M derived: sum of 3 quarters · filed 2026-05-01 | $6.85M derived: sum of 4 quarters · filed 2026-05-01 |
| 2025-12-31 | $2.13M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $2.60M derived: sum of 2 quarters · filed 2026-02-27 | $5.28M derived: sum of 3 quarters · filed 2026-02-27 | $6.92M 10-K · filed 2026-02-27 |
| 2025-09-30 | $469.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $3.15M derived: sum of 2 quarters · filed 2025-11-07 | $4.79M 10-Q · filed 2025-11-07 | $11.64M derived: sum of 4 quarters · filed 2026-02-27 |
| 2025-06-30 | $2.68M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-01 | $4.33M 10-Q · filed 2025-08-01 | $11.17M derived: sum of 3 quarters · filed 2026-02-27 | $12.63M derived: sum of 4 quarters · filed 2026-02-27 |
| 2025-03-31 | $1.64M 10-Q · filed 2025-05-02 | $8.49M derived: sum of 2 quarters · filed 2026-02-27 | $9.94M derived: sum of 3 quarters · filed 2026-02-27 | $11.46M derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-12-31 | $6.84M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $8.30M derived: sum of 2 quarters · filed 2026-02-27 | $9.82M derived: sum of 3 quarters · filed 2026-02-27 | $11.15M 10-K · filed 2026-02-27 |
| 2024-09-30 | $1.46M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-08 | $2.97M derived: sum of 2 quarters · filed 2024-11-08 | $4.31M 10-Q · filed 2024-11-08 | |
| 2024-06-30 | $1.52M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-02 | $2.85M 10-Q · filed 2024-08-02 | ||
| 2024-03-31 | $1.34M 10-Q · filed 2024-05-03 | |||
| 2023-12-31 | $15.10M 10-K · filed 2026-02-27 | |||
| 2022-12-31 | $2.61M 10-K · filed 2025-02-28 | |||
| 2021-12-31 | $499.00K 10-K · filed 2024-02-28 | |||
| 2020-12-31 | $23.00K 10-K · filed 2023-02-28 | |||
| 2019-12-31 | $28.00K 10-K · filed 2022-02-28 | |||
| 2018-12-31 | $6.00K 10-K · filed 2020-03-13 | |||
| 2017-12-31 | $24.00K 10-K · filed 2019-03-22 | |||
| 2016-12-31 | $27.00K 10-K · filed 2018-03-20 | |||
| 2014-12-31 | $6.00K 10-K · filed 2017-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| BioNexus Gene Lab Corp (BGLC) | $0.004B |